Get the Stockscreener App
1.32
3.65%
-0.05
After Hours:
1.32
Lyra Therapeutics Inc stock is traded at $1.32, with a volume of 29,393.
It is down -3.65% in the last 24 hours and down -35.92% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$1.37
Open:
$1.39
24h Volume:
29,393
Relative Volume:
0.35
Market Cap:
$2.34M
Revenue:
$770.00K
Net Income/Loss:
$-38.84M
P/E Ratio:
-0.0929
EPS:
-14.2049
Net Cash Flow:
$-43.02M
1W Performance:
-25.42%
1M Performance:
-35.92%
6M Performance:
-80.44%
1Y Performance:
-86.56%
1-Day Range:
$1.32
$1.40
1-Week Range:
$1.32
$1.90
52-Week Range:
$1.32
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Compare LYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
1.32 | 2.43M | 770.00K | -38.84M | -43.02M | -14.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-07-24 | Downgrade | Jefferies | Buy → Hold |
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-23 | Resumed | BTIG Research | Buy |
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Analyst Upgrade: How much upside does Lyra Therapeutics Inc haveJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Lyra Therapeutics Faces Nasdaq Delisting Battle After Clinical Setback - AD HOC NEWS
Lyra Therapeutics (LYRA) Faces Nasdaq Delisting - GuruFocus
Lyra Therapeutics Faces Nasdaq Delisting Over Shell Company Concerns, Capital Shortfall - marketscreener.com
Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell - TipRanks
Lyra Therapeutics Received Notice of Delisting - TradingView
What is the dividend yield of Lyra Therapeutics IncMarket Risk Analysis & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Sectors: Can Lyra Therapeutics Inc grow without external funding2025 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
What is the dividend yield of Lyra Therapeutics Inc.July 2025 EndofMonth & Verified Swing Trading Watchlist - mfd.ru
Should I buy Lyra Therapeutics Inc. stock nowWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Downgrade Watch: Will Lyra Therapeutics Inc benefit from green energy policies2025 Retail Activity & Consistent Income Trade Recommendations - baoquankhu1.vn
How Lyra Therapeutics Inc. stock reacts to Fed rate cutsFederal Reserve Announcements & Fast Growing Portfolio Trading - bollywoodhelpline.com
How cyclical is Lyra Therapeutics Inc.’s revenue streamPortfolio Performance Summary & Accurate Intraday Trading Signals - Bollywood Helpline
Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch - RTTNews
Aug Spikes: Is Lyra Therapeutics Inc stock a good pick for beginnersJuly 2025 Recap & Consistent Return Strategy Ideas - baoquankhu1.vn
Bearish Setup: Will Cheniere Energy Inc stock hit new highs in YEARWeekly Loss Report & Safe Entry Point Identification - baoquankhu1.vn
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
How much upside does Lyra Therapeutics Inc. have2025 Valuation Update & Weekly Sector Rotation Insights - Bollywood Helpline
Take Profit: Is CRTO forming bullish engulfing patternsWeekly Trade Report & Verified Technical Signals - baoquankhu1.vn
EV Market: Will Lyra Therapeutics Inc stock maintain momentum in 2025Analyst Downgrade & Weekly Return Optimization Plans - Bộ Nội Vụ
Lyra Therapeutics suspends further development of LYR-210 - Yahoo Finance
Lyra Therapeutics halts development of lead CRS treatment By Investing.com - Investing.com Nigeria
Mass. biotech company lays off entire workforce as cash dwindles - nbcboston.com
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Watertown biotech suspends drug development and eliminates workforce as cash dwindles - The Business Journals
Lyra Therapeutics, Inc. Announces Termination of Jason Cavalier as Chief Financial Officer - marketscreener.com
LYRA Plunges 55% After Company Halts Lead Program And Begins Strategic Review - Nasdaq
Why Is Lyra Therapeutics Stock (LYRA) Down Today? - TipRanks
Lyra Therapeutics plunges after halting development of lead nasal drug - TradingView
Lyra Therapeutics Inc terminates CEO Maria Palasis and CFO Jason CavalierSEC filing - marketscreener.com
Lyra Therapeutics halts development of lead CRS treatment - Investing.com
Lyra Therapeutics Provides Corporate Update - The Manila Times
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Is Lyra Therapeutics Inc. stock attractive after correctionJuly 2025 Fed Impact & Verified Entry Point Signals - Улправда
Can Lyra Therapeutics Inc. stock attract ESG capital inflowsWeekly Trade Review & Daily Profit Maximizing Trade Tips - Улправда
Published on: 2026-01-08 23:57:46 - Улправда
What momentum indicators show for Lyra Therapeutics Inc. stock2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - ulpravda.ru
ulpravda> 2026> How CHCT stock benefits from tech adoptionRecession Risk & Trade Opportunity Analysis Reports - ulpravda.ru
Is Lyra Therapeutics Inc. stock attractive for income investors2025 Technical Patterns & Weekly Breakout Stock Alerts - Улправда
Can Lyra Therapeutics Inc. stock sustain revenue growthSwing Trading Ideas & Our Picks = Your Future Gains - Улправда
Breakouts Watch: How supply chain issues affect Lyra Therapeutics Inc stockWeekly Investment Recap & Real-Time Stock Entry Alerts - Bộ Nội Vụ
Would You Accumulate or Wait on Hoac Foods India Limited (HOACFOODS)Earnings Miss Alerts & Small Investment Growth Tips - bollywoodhelpline.com
Will Lyra Therapeutics Inc. stock outperform value stocks2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 0.3% – Time to Buy? - Defense World
LYRA (Lyra Therapeutics) EV-to-OCF : -0.46 (As of Dec. 22, 2025) - GuruFocus
Can Lyra Therapeutics Inc. stock surprise with earnings upside2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - Bölüm Sonu Canavarı
Is Lyra Therapeutics Inc. stock a buy for dividend growthJuly 2025 Movers & Low Risk High Win Rate Stock Picks - Улправда
Lyra Therapeutics Earnings Notes - Trefis
Take Profit: Will Lyra Therapeutics Inc. stock outperform value stocksPortfolio Performance Report & Expert Curated Trade Setup Alerts - Улправда
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):